SESSION 8: PERIPHERAL T/NK-CELL LYMPHOMAS
ESA VERSUS MESA WITH SANDWICHED RADIOTHERAPY IN PATIENTS WITH EARLY-STAGE NATURAL KILLER/T-CELL LYMPHOMA: A MULTICENTRE, RANDOMISED, PHASE 3, NON-INFERIORITY TRIAL abstract
H.-J. Zhong, S. Cheng, X. Zhang, B. Xu, et al.
The study authors conclude that low-intensity ESA with sandwiched radiotherapy is highly effective and non-intravenous treatment, with low toxicity and outpatient basis, and can be considered as first-line treatment option in newly diagnosed early-stage NKTL.
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T-CELL LYMPHOMA: COMPARABLE OUTCOMES OF HAPLOIDENTICAL VS. MATCHED DONORS. A CIBMTR & EBMT ANALYSIS. abstract
P. Dreger, M. Ngoya, C. Litovich, H. Finel, et al.
The study authors conclude that their data, the largest study to date, confirm that alloHCT can result in durable PFS in a sizable proportion of patients with ALCL, AITL, and PTCL-NOS. The outcome of haploHCT in PTCL is comparable to that of matched donor alloHCT, suggesting that haploHCT might be a valid alternative in this setting.
LACUTAMAB IN PATIENTS (PTS) WITH ADVANCED MYCOSIS FUNGOIDES (MF) ACCORDING TO KIR3DL2 EXPRESSION: EARLY RESULTS FROM THE TELLOMAK PHASE 2 TRIAL abstract
M. Bagot, Y. Kim, P. L. Zinzani, S. Dalle, et al.
The study authors conclude that Lacutamab met the predefined threshold of activity in the KIR3DL2 expressing MF cohort required to expand recruitment to 50 pts. The safety profile is reassuring and consistent with previous phase 1 data. Updated results on all stage 1 pts from cohorts 2 and 3 will be presented.
MULTI-CENTER PHASE II STUDY OF ROMIDEPSIN PLUS LENALIDOMIDE FOR PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA (PTCL) abstract
J. Ruan, J. M Zain, B. Palmer, B. Borko Jovanovic, et al.
The study authors conclude that their study provides the first demonstration that chemo-free biologic combination of romidepsin and lenalidomide is feasible and effective as initial therapy for PTCL patients who are not candidates for cytotoxic chemotherapy. They also conclude that their data justify further evaluation of such novel agents as a frontline strategy.
THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS abstract
S. M. Horwitz, A. J. Moskowitz, N. Mehta-Shah, E. D. Jacobsen, et al.
The study authors conclude that duvelisib and romidepsin (DR) is highly active in R/R PTCL. Adding romidepsin to duvelisib 75 mg BID is safe and reduces Gr 3-4 transaminitis compared to duvelisib at the same dose. The high rates of CR and frequent bridging to allotransplant support the value of DR for patients with R/R PTCL.
EARLY SAFETY AND EFFICACY DATA FROM A PHASE I/II TRIAL OF DZD4205, A SELECTIVE JAK1 INHIBITOR, IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA abstract
W.-S. Kim, D.-H. Yoon, Y. Song, Y. Koh, et al.
The study authors conclude that early results from this ongoing phase I/II study suggest good tolerability and promising anti-tumor efficacy of DZD4205 in r/r PTCL, indicating its potential as a therapeutic option for this unmet medical need.